Single-tube, dual channel pentaplexing for the identification of Candida strains associated with human infection

Mohd Hanif Jainlabdin1,2, Ambalika Batra2, Edith Sánchez Paredes3, Francisca Hernández Hernández3, Guoliang Fu4 & Jorge Tovar-Torres1

Invasive candidiasis is one of the most common nosocomial fungal infections worldwide. Delayed implementation of effective antifungal treatment caused by inefficient Candida diagnosis contributes to its notoriously high mortality rates. The availability of better Candida diagnostic tools would positively impact patient outcomes. Here, we report on the development of a single-tube, dual channel pentaplex molecular diagnostic assay based on Multiplex Probe Amplification (MPA) technology. It allows simultaneous identification of C. auris, C. glabrata and C. krusei, at species-level as well as of six additional albicans and non-albicans pathogenic Candida at genus level. The assay overcomes the one-channel one-biomarker limitation of qPCR-based assays. Assay specificities are conferred by unique biomarker probe pairs with characteristic melting temperatures; post-amplification melting curve analysis allows simple identification of the infectious agent. Alerting for the presence of C. auris, the well-characterised multi-drug resistant outbreak strain, will facilitate informed therapy decisions and aid antifungal stewardship. The MPA-Candida assay can also be coupled to a pan-Fungal assay when differentiation between fungal and bacterial infections might be desirable. Its multiplexing capacity, detection range, specificity and sensitivity suggest the potential use of this novel MPA-Candida assay in clinical diagnosis and in the control and management of hospital outbreaks.

Invasive fungal infections (IFIs) are a significant threat to immunocompromised patients1. The immune system of healthy individuals may also be compromised by severe health conditions such as burns, diabetes mellitus, organ transplantation, human immunodeficiency virus infections and disorders such as leukaemia and other malignancies. Invasive and aggressive medical practices and treatments such as surgery, the use of catheters, radiation and chemotherapy put patients at high risk from invasive fungal infections2. It is estimated that invasive fungal infections claim the lives of around 1.5 million people every year but epidemiological data are often negatively affected by challenges associated with laboratory diagnoses such as inefficient methodology and inadequate regional logistics3.

Among the prevalent fungal pathogens, species of the yeast Candida are a leading causes of invasive fungal disease and are commonly associated with nosocomial infections4. Candida species contribute 10–20% of hospital-associated infections5 and are responsible for 5–15% of bloodstream infections among immunocompromised and extreme age patients6. More than 90% of invasive candidiasis cases are caused by C. albicans, C. glabrata, C. parapsilosis, C. tropicalis and C. krusei7,8. In the United Kingdom, the most recent estimate of invasive candidiasis was 5,142 cases in 2013, with population incidence of 3.1 per 100,000 and 10.1 per 100,000 for candidemia and invasive candidiasis respectively9. Improving the diagnosis and management of candidiasis is essential for the timely prescription of correct therapeutic drugs to patients and the acquisition of reliable epidemiological data5,10. It is also important for the management and control of nosocomial outbreaks11.

Accurate identification of pathogenic Candida to species-level is key for effective treatment, as not all species are equally susceptible to individual antifungal drugs12. This is evidenced by intrinsic resistance of C. krusei to
fluconazole and lower susceptibility of C. glabrata towards most antifungal drugs, including amphotericin B[13,14].
Along with species-level identification, the ability to detect other medically important species has become crucial as the emergence of non-albicans Candida species continues to rise. In recent years, multi-drug resistant C. auris outbreaks have been reported across major hospitals in the UK[15,16]. Public Health England Mycology Reference Laboratory has reported that all C. auris isolates in the UK are resistant to fluconazole, with variable resistance to polyens (~20% for amphotericin B) and echinocandins (~10%)[17]. First reported in Japan as the cause of an ear infection[18], C. auris has been shown to have a close genetic relationship with C. haemulonii. It is crucial therefore to differentiate between these two species for the efficient management and control of nosocomial C. auris outbreaks, as under such circumstances the isolation of carriers and the release of non-carriers is a clinical priority[16,19].

Recent advances in the development of new and reliable methods of fungal nucleic acid detection hold promise for the early identification of fungal pathogens[19,20]. Conventional microbiological techniques such as blood cultures are positive in only 38–50% of proven invasive candidiasis[21,22], while immunological detection of fungal cell wall markers suffer from low specificity and sensitivity[23]. Real-time PCR-based molecular methods such as GeneChip kit (PrimerDesign), ViPrimePLUS Candida albicans qPCR kit (Vivantis) and LumineX xTAG Fungal Assay (LumineX Molecular Diagnostics) appear promising. However, these and similar products are often limited in the number of species that can be identified in a single assay and suffer from low multiplexing capacity.

Multiplex Probe Amplification (MPA) was developed as an alternative biomarker amplification method that overcomes such limitations[8]. It allows detection of multiple analytes in a single fluorescence detection channel; up to six probes with a unique melting temperature can be labelled with the same fluorophore and detected. Here we report on the development of MPA technology for identification of the main Candida strains that cause invasive candidiasis. As a pre-clinical, proof of concept study, an MPA-Candida assay was engineered to incorporate a pan-Candida biomarker probe able to identify at genus level the nine Candida species most frequently associated with candidiasis (C. albicans, C. dubliniensis, C. tropicalis, C. parapsilosis, C. guilliermondii, C. haemulonii, C. krusei, C. glabrata and C. auris). In addition, three species-specific biomarker probes were incorporated for the individual identification of multidrug-resistant C. auris, C. glabrata and C. krusei. The in-vitro characterisation of the MPA-Candida assay reported here highlights the potential of this novel molecular tool in clinical diagnosis of candidiasis, disease management, and in the control of nosocomial outbreaks. Informed prescription of the most suitable chemotherapy at the first time of asking will not only benefit patients but could also contribute to antifungal stewardship efforts worldwide.

**Results**

**Identification and characterisation of fungal DNA biomarkers.** The basic principles of MPA technology are described and illustrated in the Methods section. Short biomarker nucleotide sequences that could reliably differentiate fungi from bacteria (pan-fungal), Candida from any other fungi (pan-Candida) and discern C. auris, C. glabrata and C. krusei from each other and from all other Candida species were identified within the rDNA locus[25-27], as described in the Methods section. The pan-fungal probe lies within the internal transcribed spacer 2 (ITS2) region (Fig. 1). Reverse BLASTing of this sequence amongst the fungi demonstrated 100% sequence similarity with 100% query cover for all top 100 hits (Table S1). Optimised universal primers ITS3 and LR1 were used to generate an amplicon containing the pan-fungal biomarker. Amplicon sizes in the range of 279 bp (Candida auris) and 451 bp (Lichtheimia corymbifera, formerly Absidia corymbifera) were obtained.

Genus-specific (pan-Candida) and species-specific Candida biomarkers lie within the D1/D2 region of the LSU rDNA gene locus (Fig. 1). C. krusei, C. glabrata and C. auris-specific probes had 100% sequence similarity with 100% query cover to their respective Candida species (Table S1). The pan-Candida probe had 100% sequence similarity with all Candida species tested. Similarity to five other fungi rarely associated with human infection was also observed with this probe (Table S1). All selected biomarker sequences showed no intraspecies strain-to-strain variability in multiple alignments (Tables S2 and S3). A forward primer pair to amplify Candida species was optimised from universal primer LR0, while the reverse primer GSCand-R, was designed specifically for the assay (Table S4). The primer set generated a 381 bp biomarker-containing amplicon for most Candida species. C. krusei, C. auris and C. guilliermondii amplicons were 370 bp in size. Nucleotide sequences for all MPA-Candida probes and amplification primers are shown in Table S4.
Candida detected in the MPA

Heat capacity (Cp) is the maximum amount of heat needed to change the temperature of one mole of a hybrid by one degree at constant pressure, which defines the melting temperature (Tm).

Design of Candida-specific MPA probes and melting curve analysis. MPA probes consist of two partly complementary oligonucleotides, the dual-labelled target-hybridising oligonucleotide (THO) and a corresponding partially complementary oligonucleotide (PCO). Each THO is fully complementary to one of the Candida-specific biomarker target sequences identified above. The pan-Candida, and C. krusei, C. glabrata and C. auris species-specific probes hybridise with high affinity to their respective targets within the hypervariable D1/D2 LSU rDNA region. The PCO sequences were engineered to have several nucleotide mismatches against their corresponding THO sequence (Table S4). All Candida biomarker target sequences are located close to each other within the LSU region and are amplified by a single set of primers (Fig. 1). Initial characterisation of all five MPA probes (THOs plus their corresponding PCO sequences) using UNAFold software allowed confirmation of their theoretical melting profiles (Fig. 2). A melting curve overlap between the C. krusei-specific probe and the internal control probe as well as between the C. auris and the C. glabrata-specific probes is apparent. However, their independent analysis is not affected under experimental conditions as each overlapping probe is labelled with a different fluorophore. The pan-Candida, C. krusei-specific and C. glabrata-specific probes were labelled with 6-carboxyfluorescein (FAM) whereas the C. auris-specific and the internal control probes were labelled with Hexachloro-fluorescein (HEX).

Experimental assembly of all MPA-Candida probes in a single reaction tube consistently generated five specific melt peaks collected in two fluorescence detection channels. C. krusei, C. glabrata and pan-Candida probes were detected in the FAM channel, whereas the C. auris and internal control probes were detected in the HEX channel (Fig. 3, panels a and b respectively). Each peak represents the maximum rate of dissociation between THO and PCO at a given temperature during melting curve analysis. These melt curves provide an important no-template control to compare against the melt curves obtained when target DNA is present and amplified in the reaction.

Design of a complementary pan-Fungal qPCR assay. To complement the functionality of the MPA-Candida assay we designed a qPCR pan-Fungal assay that may be used alongside for enhanced fungal detection range. It operates under the same DNA amplification conditions and, when used, allows detection of a wider range of clinically relevant fungal pathogens. Fluorescence emission following qPCR biomarker amplification is monitored at 465 nm in the FAM channel. This reaction tube also contains a HEX-labelled internal control probe as well as between the C. krusei and C. glabrata-specific probes is apparent. However, their independent analysis is not affected under experimental conditions as each overlapping probe is labelled with a different fluorophore. The pan-Candida, C. krusei-specific and C. glabrata-specific probes were labelled with 6-carboxyfluorescein (FAM) whereas the C. auris-specific and the internal control probes were labelled with Hexachloro-fluorescein (HEX).

Experimental assembly of all MPA-Candida probes in a single reaction tube consistently generated five specific melt peaks collected in two fluorescence detection channels. C. krusei, C. glabrata and pan-Candida probes were detected in the FAM channel, whereas the C. auris and internal control probes were detected in the HEX channel (Fig. 3, panels a and b respectively). Each peak represents the maximum rate of dissociation between THO and PCO at a given temperature during melting curve analysis. These melt curves provide an important no-template control to compare against the melt curves obtained when target DNA is present and amplified in the reaction.

Analytical specificity of the combined MPA-Candida and pan-Fungal assays. The specificity of the MPA-Candida assay was tested independently using recombinant plasmids harbouring C. albicans, C. dubliniensis, C. krusei, C. glabrata, C. auris, C. parapsilosis, C. tropicalis, C. haemulonii, C. guillermondii target biomarkers. Following DNA amplification their corresponding melt curves were analysed. All nine Candida species showed reduction/ablation of their melt peaks at 40°C, corresponding to the pan-Candida probe, when compared to their corresponding no-template controls (Fig. 4). This demonstrates the assay’s capability to identify at genus level the nine Candida species most commonly associated with human infection. In addition, specific identification of three important drug-resistant Candida species, namely C. krusei, C. glabrata and C. auris, was demonstrated by additional melt peak reductions at 30°C and 46°C in the FAM channel and at 48°C in the HEX channel respectively (Fig. 4, panels b–d). None of the other Candida species tested showed a melt curve decrease at those temperatures thus demonstrating the species-specificity of the assay for C. auris, C. glabrata and C. krusei.

Assay specificity was also tested using genomic DNA (Table 1). None of the heterologous DNAs tested were detected in the MPA-Candida assay; the internal control present in every sample demonstrated assay functionality and ruled out the possibility of false negative results. The pan-Fungal assay identified all nine Candida species...
tested as well as a range of pathogenic filamentous fungi, including *Aspergillus fumigatus*, *Fusarium solani*, *Penicillium rubens* and *Mucor circinelloides*. Genomic DNA from bacteria that form part of the normal human flora, including *Staphylococcus epidermidis*, *Staphylococcus aureus*, *Proteus mirabilis* and *Escherichia coli*, was not detected under the conditions used. All bacterial and fungal genomic DNAs were tested at 10⁵ genome equivalents (GEs) per reaction (Table 1; Fig. S1). DNA amplification of the internal control was consistently detected in the HEX detection channel. Early amplification (Cₚ = 16) of the same *E. coli* genomic DNA samples was observed using the universal bacterial 16S primer set.

**Assay sensitivity and limits of detection.** The limits of detection of the MPA-*Candida* assay were determined using a range of 10⁰–10⁹ GEs. DNA amplification profiles and the magnitude of melting curve reductions observed were evaluated against their corresponding no-DNA controls (NDC; Fig. 5). The amplification cycle threshold was set at 45 cycles to avoid inconclusive late amplification. Crucially, in this assay, interpretation of the specificity of amplification relies totally on the melt curve analysis derived from the data collected in just two detection channels, FAM and HEX.

Measurable reductions in the pan-*Candida* peaks compared to no DNA controls allowed genus-level identification of all samples, down to 10 GEs for *C. krusei* and *C. auris* and 100 GEs for *C. albicans, C. dubliniensis, C. glabrata, C. parapsilosis, C. tropicalis, C. haemulonii* and *C. guilliermondii* (Fig. 5 and Table 2). The *C. glabrata*-specific probe (46 °C peak in FAM channel) detected down to 100 *C. glabrata* GEs while the *C. krusei*- and *C. auris*-specific probes (30 °C peak in FAM channel and 48 °C peak in HEX channel) detected down to 10 GEs, a 10-fold higher sensitivity compared to the *C. glabrata* probe (Fig. 5, panels a to d).

The limits of detection of the pan-*Fungal* assay were determined from amplification curves monitored in the FAM channel. In general, *Candida* species can be routinely detected down to 10 GEs except for *C. glabrata, C. tropicalis* and *C. guilliermondii* which required a minimum of 100 GEs in the reaction. The limits of detection for both the MPA-*Candida* and pan-*Fungal* assays are summarised in Tables 2 and 3 respectively.

**Amplification efficiency and reproducibility of the pan-*Fungal* assay.** Amplification efficiency of the pan-*Fungal* quantitative assay was calculated from the slopes generated in independent experiments using
Figure 4. Melt curve analysis specificity of the MPA-Candida assay. FAM and HEX channel post-amplification melt curve profiles of nine different Candida species (dotted lines) compared to their corresponding no-template controls (solid lines). (a) Genus-level identification of the indicated Candida species is demonstrated by ablation of the pan-Candida peak in the FAM channel; decrease of the internal control (IC) peak in the HEX channel confirms assay functionality. (b,c) Species-specific identification of C. krusei and C. glabrata respectively, as demonstrated by a significant reduction in their corresponding melt peaks in the FAM channel; note that in both cases the pan-Candida peak is also ablated. (d) Species-specific identification of C. auris, as demonstrated by a significant reduction in its melt peak in the HEX channel and ablation of the pan-Candida peak in the FAM channel. In all cases diagnosis is supported by the corresponding DNA amplification curves and associated Ct values (Table S5).
In this study, biomarkers for the detection of all fungal species (pan-fungal), all Candida species (pan-Candida) and the species-specific identification of C. krusei, C. glabrata and C. auris were incorporated into a novel molecular diagnostic assay based on MPA technology. C. auris, C. glabrata and C. krusei were selected for species-level identification due to their well-known antifungal drug resistant phenotypes. In this version of the assay, detection range was widened by incorporating genus-level detection of six additional Candida species capable of causing human invasive candidiasis, namely C. albicans, C. dubliensis, C. tropicalis, C. guilliermondii, C. parapsilosis and C. haemulonii. The MPA-Candida assay contains probe pairs from the variable D1/D2 domains of the LSU rDNA locus. The initial 381-nucleotide sequence from the 5′ end of the LSU region has been shown to contain great intra-genus sequence diversity for Candida species and has been used previously to distinguish at species-level all clinically relevant Candida species. BLAST analysis of the pan-Candida probe sequence found no identity to any prokaryotic or eukaryotic gene sequences, with the exception of five environmental yeasts, namely Yamadazyma olivae, Kregervanrija pseudodelftensis, Zygosaccharomyces rouxii, Spathaspora sp and Saccharomyces

### Table 1. Specificity of the MPA-Candida and pan-Fungal assays.

| Species          | MPA-Candida assay | Pan-Fungal assay |
|------------------|-------------------|-----------------|
|                  | Melting curve analysis | C<sub>i</sub> value | C<sub>i</sub> value |
|                  | FAM | HEX | FAM | HEX | FAM | HEX | FAM | HEX | FAM | HEX | FAM | HEX |
| Candida           |     |     |     |     |     |     |     |     |     |     |     |     |
| C. albicans      | −   | +   | −   | +   | −   | 23.40 | 26.00 | 22.00 | 21.00 |
| C. krusei        | +   | −   | +   | −   | 22.20 | 26.20 | 22.90 | 25.60 |
| C. glabrata      | −   | +   | +   | −   | 24.40 | 26.50 | 24.30 | 24.80 |
| C. auris         | −   | +   | −   | +   | 23.60 | 29.00 | 23.00 | 26.20 |
| C. haemulonii    | −   | +   | +   | −   | 24.60 | 27.80 | 21.00 | 26.00 |
| C. dubliensis    | −   | +   | +   | −   | 23.60 | 28.00 | 22.00 | 26.30 |
| C. parapsilosis  | −   | +   | −   | +   | 23.90 | 26.90 | 21.80 | 25.40 |
| C. tropicalis    | −   | +   | −   | +   | 23.50 | 26.00 | 21.00 | 26.00 |
| C. guilliermondii| −   | +   | −   | +   | 23.60 | 26.50 | 22.90 | 26.50 |
| Moulds*          |     |     |     |     |     |     |     |     |     |
| A. fumigatus     | −   | +   | −   | +   | −   | 28.10 | 22.90 | 23.40 |
| F. solani        | −   | +   | −   | +   | −   | 28.50 | 21.10 | 23.20 |
| P. rubens        | −   | +   | −   | +   | −   | 27.10 | 16.60 | 20.10 |
| M. circinelloides| −   | +   | +   | −   | 28.00 | 17.00 | 24.10 |
| Bacteria*        |     |     |     |     |     |     |     |     |     |
| S. aureus        | −   | +   | −   | +   | −   | 29.70 | −   | 22.80 |
| S. epidermidis   | −   | +   | +   | −   | −   | 28.90 | −   | 23.50 |
| P. mirabilis     | −   | +   | −   | +   | −   | 28.40 | −   | 23.00 |
| E. coli          | −   | +   | −   | +   | −   | 28.00 | −   | 23.20 |

*Fungal and bacterial genomic DNAs were tested at 10<sup>5</sup> genome equivalent per reaction. C<sub>i</sub>: Threshold Cycle, the cycle intersection at the point where the curve first clearly rises off baseline value; FAM: Detection channel (465 nm/510 nm); HEX: Detection channel (533 nm/580 nm); CK: C. krusei-specific peak (30 °C); PC: Pan-Candida peak (40 °C); CG: C. glabrata-specific peak (46 °C); CA: C. auris-specific peak (48 °C); IC: Internal Control-specific peak (34 °C); PF: pan-fungal; +: Change in melt curve detected; −: No change detected.

Discussion

In this study, biomarkers for the detection of all fungal species (pan-fungal), all Candida species (pan-Candida) and the species-specific identification of C. krusei, C. glabrata and C. auris were compared. Given the importance of multi-drug resistant C. auris for clinical and epidemiological studies, we compared the performance of the MPA-Candida assay against a commercially available single-purpose C. auris identification kit (Genesig, PrimerDesign). As can be seen in Fig. 7, comparable C. auris identification efficiency was observed under the same experimental conditions, with correlation coefficient R<sup>2</sup> = 0.997, PCR efficiency (E) = 79.02% for the Genesig kit and R<sup>2</sup> = 0.997, E = 125.09% for the MPA-Candida assay C. auris species-specific identification and R<sup>2</sup> = 0.993, E = 73.57% for the Candida genus-specific identification, respectively. In contrast to the Genesig kit, the MPA-Candida assay showed no cross-reactivity with genomic DNA from C. haemulonii, a close relative of C. auris (data not shown).

Comparison of assay performance.

Assay reproducibility was assessed using target biomarker dilutions spanning five orders of magnitude, from 10<sup>6</sup> to 10<sup>2</sup> plasmid DNA copies per reaction. The pan-Fungal assay reproducibly identified all Candida species over the range of dilutions tested, with intra- and inter-assay CV values lower than 5% (Tables S7 and S8 respectively).
Figure 5. Amplification profiles and melt curve analyses of genomic DNA in MPA-Candida assays. Amplification reactions containing a range of 1 to $10^5$ GEs per reaction were set up. Post-amplification melt curve analysis was then carried out. Amplification plots of *C. albicans* (a), *C. krusei* (b) and *C. glabrata* (c) and their corresponding melt curve profiles are shown demonstrating changes in the pan-Candida peaks proportional to the number of GEs present in the reaction. Similar results can be seen for *C. krusei* and *C. glabrata* at their corresponding species-specific peaks in the FAM channel. (d) Amplification plots of *C. auris* and their corresponding melt curve profiles showing proportional changes to their pan-Candida (i) and *C. auris*-specific (ii) peaks in the FAM and HEX channels respectively. The horizontal dotted line is fixed as the threshold value of fluorescence.
cerevisiae, the latter phylogenetically related to Candida30,31. Cross-detection of S. cerevisiae by the pan-Candida probe is not of medical concern as invasive infections caused by S. cerevisiae are rare compared to those caused by Candida and standard antifungal therapy with fluconazole is efficient in controlling such infections32,33.

The pan-fungal probe used in this study was selected from the ITS2 region, which was amplified using the universal primer set ITS3 and LR127. Although there is no single locus for global fungal identification, the whole ITS region (ITS1-5.8-ITS2) is generally accepted as a universal fungal DNA barcode26. To ensure assay functionality and avoid false negative results, a unique internal control probe sequence was designed and incorporated into both MPA-Candida and pan-Fungal assays. Monitoring the presence of the internal control plasmid sequence was independent of the presence or absence of fungal target sequences in the assay.

### Table 2. Limits of detection of the MPA-Candida assay.

| Species        | Detection channel(s) | Limit of detection (GEs) | C<sub>t</sub> <45 cut-off value |
|----------------|----------------------|--------------------------|-------------------------------|
| C. auris       | FAM, HEX             | 10                       | 43.60, 32.40                  |
| C. krusei      | FAM                  | 10                       | 41.00                         |
| C. glabrata    | FAM                  | 100                      | 41.30                         |
| C. albicans    | FAM                  | 100                      | 37.10                         |
| C. dubliniensis| FAM                  | 100                      | 35.60                         |
| C. parapsilosis| FAM                  | 100                      | 36.50                         |
| C. tropicalis  | FAM                  | 100                      | 37.90                         |
| C. guilliermondii | FAM                | 100                      | 36.50                         |
| C. haemulonii  | FAM                  | 100                      | 37.00                         |

### Table 3. Limits of detection of the pan-Fungal assay.

| Species         | Limit of detection (GEs) | C<sub>t</sub> <45 cut-off value in FAM |
|-----------------|--------------------------|---------------------------------------|
| Aspergillus flavus| 10                       | 40.00                                 |
| C. auris        | 10                       | 42.00                                 |
| C. krusei       | 10                       | 41.00                                 |
| C. albicans     | 10                       | 40.00                                 |
| C. dubliniensis | 10                       | 41.30                                 |
| C. parapsilosis | 10                       | 41.50                                 |
| C. haemulonii   | 10                       | 40.00                                 |
| C. glabrata     | 100                      | 43.10                                 |
| C. tropicalis   | 100                      | 35.00                                 |
| C. guilliermondii| 100                     | 37.30                                 |

### Figure 6. Pan-Fungal assay standard curve. Standard curve generated by plotting the mean C<sub>t</sub> values as a function of target DNA concentration. Ten-fold serial dilutions (10<sup>6</sup> to 10<sup>2</sup> GEs) of Candida DNA were analysed in three independent experiments, each with three replicates per sample. Error bars represent standard deviations (SD) of C<sub>t</sub> values. Confidence intervals (CI) of C<sub>t</sub> mean values are indicated by the dashed lines.

Y = -3.514(x) + 45.44

R<sup>2</sup> = 0.9992
In vitro testing of the MPA-Candida assay demonstrated its capacity for genus-level identification of nine medically important Candida species using a pan-Candida probe i.e., C. albicans, C. dubliniensis, C. parapsilosis, C. tropicalis, C. guilliermondii, C. haemulonii, C. krusei, C. glabrata and C. auris. Drug-resistant species C. krusei, C. glabrata and C. auris can also be simultaneously identified at species level by their corresponding species-specific probes. This should allow informed decisions to be made regarding chemotherapy. For example, an infection caused by C. albicans would give a positive diagnosis through reduction of the pan-Candida melting peak (Figs 4a and 5a). The concomitant absence of any significant change in the species-specific melting peaks for C. auris, C. glabrata or C. krusei would suggest the use of first-line antifungals such as fluconazol or itraconazole, instead of alternative and more costly second line antifungals recommended for C. auris or C. glabrata infections (e.g., micafungin, caspofungin, amphoterin B). In addition, kingdom-level identification by the pan-Fungal assay should strengthen clinical decisions where the prokaryotic or eukaryotic nature of the infectious agent is uncertain.

Intra-specific variation within the fungal rDNA locus has been shown to be minimal\(^\text{24,35}\). This includes the ITS region and the 26S D1/D2 region (target site for the pan-Candida and species-specific probes). Irinyi et al (2015) conducted extensive nucleotide diversity (\(\pi\)) and polymorphic site proportion analysis using 176 fungal species with a minimum of two clinical isolates per species. Kurtzman & Robnett (1997) reported intra-specific variation within the ~380 bp Candida D1/D2 region to be in the range of 0 to 2 nucleotides. Analysis of the intra-specific variability within the nucleotide sequences targeted by the MPA-Candida diagnostic probes using nucleotide sequences from reference and multiple clinical isolates/stains for each of the Candida species used in this study found no evidence of intra-species variability in their target regions (Tables S2 and S3). For C. auris, we included representative sequences from the most important geographical clades (East Asia, South Asia, Africa and South America). Taken together, these findings suggest that most if not all natural clinical isolates/stains of a particular Candida species should be readily identified by the MPA-Candida assay described in this study.

Inter-specific variability within the D1/D2 region of the large ribosomal subunit is, on the other hand, exquisit. It has been extensively employed in fungal taxonomical classification and in the molecular identification of mould and yeast species, including Candida\(^\text{28,35}\). Table 1 shows that genomic DNA from a range of moulds and bacteria frequently associated with human colonisation/infection is not detected by the MPA-Candida assay; neither is genomic DNA of human origin. Extensive sequence homology searches using non-redundant nucleotide sequence databases that include bacterial, human, mould and yeast DNA sequences found no identical target sequences other than those reported on Table S1. Taken together, these data strongly suggest that the possibility of false positive diagnostic results due to inter-species cross-reactivity is very low. It is acknowledged however that, as for every other molecular diagnostic test, ruling out the possibility of unintended assay cross-reactivity would require more extensive sampling across the taxonomic range.

The fact that five different MPA probes are labelled with either of two different fluorophores and analysed using two fluorescence detection channels provides a crucial advantage over other real-time qPCR diagnostic tests which use standard hydrolysis probes and are limited to one detection channel per biomarker\(^\text{24}\). The pan-Candida, C. krusei-specific and C. glabrata-specific probes were labelled with FAM; the C. auris-specific and internal control probes were labelled with HEX. Although MPA allows labelling of up to six different probes with the same fluorophore we sought to avoid analytical ambiguity by using two rather than a single detection channel. The C. auris-specific probe has a melting temperature almost identical to that of the C. glabrata-specific probe and would overlap significantly in a single channel; the internal control probe has a melting temperature that is less than 5 °C different to the C. krusei-specific probe. Ideally, the melting temperature between the probes labelled with the same fluorophore should differ by 5–7 °C. During assay optimisation assembly of the pan-Candida and C. glabrata-specific probes labelled with FAM at equivalent concentrations led to a masking of the C. glabrata signal; reducing the pan-Candida probe concentration to 0.2 µM resolved this issue. The reason for this observation is unclear but probe interference in MPA assays has been noted before\(^\text{24}\).
A separate pan-Fungal assay could assist clinicians in ruling out non-fungal infections before proceeding with the diagnosis for candidiasis. A pan-Fungal assay complementary to the MPA-\textit{Candida} assay was engineered using a pan-fungal probe that targets the whole ITS2 region. The ITS2 region has been widely used in fungal phylogenetic studies and in detecting fungal pathogens in a range of PCR platforms\cite{36,37}. Detection channels and the reaction protocol for the pan-Fungal assay are consistent with those used in the MPA-\textit{Candida} assay, which enables simultaneous running of both reactions and result analysis in a single run. As the pan-Fungal assay is not based on MPA technology only an amplification curve is needed to monitor target amplification. The pan-Fungal assay is more straightforward to analyse and could save the precious DNA material and cut the cost for unnecessary diagnosis processes. However, combining the current MPA-\textit{Candida} and pan-Fungal assays into a single-tube, single-detection channel reaction might be feasible.

The MPA-\textit{Candida} assay offers post-amplification melt peak analysis for identification of drug sensitive and drug resistant \textit{Candida} species. In the presence of each target, the corresponding melting peak is either reduced in magnitude or ablated when compared with the no-template control. All nine \textit{Candida} species were detected by the pan-\textit{Candida} probe and each drug resistant species (\textit{C. auris}, \textit{C. glabrata} and \textit{C. krusei}) was simultaneously identified by their corresponding species-specific probe. A slight reduction of the \textit{C. krusei} melting peak was noted in the presence of non-\textit{krusei Candida} DNA throughout this study. This phenomenon has been described as “shrunk neighbouring peaks” by Fu et al.\cite{34} and does not affect the diagnostic specificity and accuracy of the assay. In the presence of \textit{C. krusei} DNA its corresponding melting peak is clearly reduced or ablated compared to a small reduction as in the presence of non-\textit{krusei Candida} DNA. Overall, assay design and melting peak distribution along two detection channels allows easy identification of one or more \textit{Candida}-specific targets in a single-tube format.

Both the MPA-\textit{Candida} and pan-Fungal assays were shown to detect down to 100 target GEs and could confidently detect 10 \textit{C. krusei} and \textit{C. auris} GEs. This range of detection is equivalent to the clinical range of candidemia of 5 to 100 CFU/ml\cite{18} and compares well with other commercially available kits. For example, SeptiFast (Roche) could detect fungal DNA in a range of 30 to 100 CFU/ml blood\cite{39}, and MycoReal \textit{Candida} kit (Ingenetix) could detect from 5 to 10 CFU/ml blood\cite{40}. In the MPA-\textit{Candida} assay, amplification of DNA from any of the \textit{Candida} species is detected in the FAM channel whereas amplification of \textit{C. auris} DNA or the internal control DNA is detected in the HEX channel. Post-amplification melt curve analysis is essential for the qualitative identification of drug-sensitive or drug-resistant species in the MPA-\textit{Candida} assay. Interestingly, although DNA amplification from a single copy of \textit{C. krusei} genomic DNA could be detected (\(C_\text{r}=42.52 \pm 2.07\)) its corresponding melting peak was not reduced significantly compared to the no-DNA control peak. Result interpretation therefore must always be guided by the melt curve analysis, especially at very low infection loads. Sensitivity testing using plasmid-cloned target DNAs demonstrated that the MPA-\textit{Candida} assay can reliably detect down to 100 copies of target DNA per reaction (Tables S7 and S8). Given that each fungal cell contains around 50 rDNA copies, 100 copies of target DNA is equivalent to a limit of detection of 2 GEs/2 CFUs. The data suggests that the molecular environment within the reaction tube is important in determining assay sensitivity.

The MPA-\textit{Candida} assay was evaluated for its capacity to identify the presence of the multi-drug resistant, outbreak strain \textit{C. auris}. Assay sensitivity was found to be up to 10 GEs per reaction at both genus- and species-level. Its limit of detection is comparable to that of the Genesig kit (PrimerDesign), a simplex \textit{C. auris} identification kit, when tested over a five order of magnitude \textit{C. auris} DNA dilution range (Fig. 7). Importantly, no cross-reactivity was observed with \textit{C. haemulonii}, a closely related species that is frequently misidentified as \textit{C. auris} by commercial biochemical-based yeast identification systems such as Vitek 2 (BioMérieux) and BD Phoenix (BD Diagnostics)\cite{41}.

In summary, the MPA-\textit{Candida} assay allows detection of five different targets in just two detection channels. The multi-drug resistant \textit{C. krusei}, \textit{C. glabrata} and \textit{C. auris} strains can be efficiently discriminated from other \textit{Candida} species by a straightforward melt curve analysis. These features would allow clinical decision making to be expedited so that the most efficient chemotherapy can be prescribed in a timely fashion, thus improving patient outcomes. The MPA-\textit{Candida} assay is suitable for adaptation to other qPCR platforms (Qiagen’s Rotor-Gene Q 2-Plex HRM, Applied Biosystems 7500), which could allow integration into laboratories that operate under conditions of limited resources.

**Methods**

**Multiplex probe amplification (MPA) probes and melting curve analysis.** Each probe for every target is composed of two oligonucleotides; a dual-labelled target-hybridising oligonucleotide (THO) and a partially-complementary oligonucleotide (PCO) (Fig. 8a). The THO binds to its intended biomarker target sequence with high affinity; it also binds to its corresponding PCO, albeit with lower affinity. The PCO incorporates mismatched nucleotides and has slightly lower annealing temperature compared to that of the THO and its fully complementary target sequence. In the absence of target DNA, the THO will bind to its corresponding PCO and will display a characteristic dissociation peak in the melt curve analysis. In the presence of DNA target sequence, the THO will preferentially anneal to its target and will be hydrolysed during the extension steps of PCR. Consequently, the post-amplification melting curve analysis will show a decreased melting peak compared to the no-target control as little or no THO:PCO hybrid can be formed. The THO:PCO hybrid probe shows maximum fluorescence at a low temperature which decreases as the probe dissociates with increasing temperatures (Fig. 8b). The highest rate of fluorescence change is observed in the melting curve analysis when 50% of the THO has dissociated from the PCO at the specific melting temperature (Fig. 8c)\cite{24}.

**Fungal strains and bacterial isolates.** Candida strains (\textit{C. albicans}, \textit{C. glabrata}, \textit{C. tropicalis}, \textit{C. dubliniensis}, \textit{C. krusei}, \textit{C. guilliermondii} and \textit{C. parapsilosis}) were a kind gift of Professor Julian Naglik (King’s College London). \textit{C. auris} (NCPF 8971) and \textit{C. haemulonii} (NCPF 8402) strains were purchased from Public
Health England, Bristol, UK. Mould and bacterial strains A. fumigatus, F. solani, M. circinelloides, P. rubens, S. aureus, S. epidermidis, E. coli, and P. mirabilis were obtained from the Molecular Microbiology laboratory, Centre for Biomedical Sciences, Royal Holloway University of London. Fungal isolates were sub-cultured onto Sabouraud-Dextrose Agar (SDA; Sigma-Aldrich) and incubated at 37° and 25 °C for yeast and mould respectively for 15–24 hours. For liquid cultures, single yeast colonies were inoculated in yeast-extract peptone dextrose (YPD) broth (Sigma-Aldrich), while bacterial isolates were cultured in Luria-Bertani (LB) broth (Merck) at 37 °C in a rotary shaker (SciQuip) for 24 hours. Following incubation, cultures were placed on ice and processed for DNA isolation immediately. The identity of all fungal isolates was confirmed by sequencing of their ribosomal DNA region and BLAST analysis (http://blast.ncbi.nlm.nih.gov).

Nucleic acids extraction. One millilitre aliquots of yeast and bacterial cultures were transferred to 1.5 ml microcentrifuge tubes and centrifuged at 16,000 × g in a bench microcentrifuge for 2 minutes to pellet the cells. The supernatant was discarded and the bacterial and yeast cell pellets were processed as follows. The bacterial cell pellet was resuspended in 60 µl of 10 mg/ml lysozyme and incubated at 37°C for 30 minutes to ensure efficient cells lysis. The yeast cell pellet was resuspended in 300 µl of lysis buffer from the Wizard Genomic DNA Purification kit (Promega). Following addition of 200 mg of 500-micron glass beads (BioSpec Products) yeast cells were homogenised with a FastPrep-24 instrument (MP Biomedicals) using five pulses with 60 seconds cooling intervals at 6.5 m/s speed setting. Cell debris was removed by centrifugation at 16,000 × g for 2 minutes, and the supernatant was transferred to fresh tubes for DNA isolation following the manufacturer instructions. Briefly,
The resulting plasmid with insert was quantified and sequenced to confirm amplicon identity. In Table 4, the reaction type, probe target, detection channel, and primer set are listed.

| Reaction Type | Probe target | Detection channel | Primer set                      |
|---------------|--------------|-------------------|---------------------------------|
| MPA           | C. krusei    | FAM               | Forward: LR0<sup>45</sup> & Reverse: GSCand (this study) |
|               | Pan-Candida  |                   |                                 |
|               | C. glabrata  |                   |                                 |
|               | C. auris     | HEX               | Forward: M13 (–20) & Reverse: M13 (–29) |
|               | Internal Control |             | Forward: M13 (–20) & Reverse: M13 (–29) |
| qPCR          | Pan-Fungal   | FAM               | Forwards: ITS3<sup>46</sup> & Reverse: LR1<sup>45</sup> |
|               | Internal Control |             |                                 |

Table 4. Description of the MPA-Candida and pan Fungal assays. FAM: 6-carboxy-fluorescein; 465 nm/510 nm; HEX: Hexachloro-fluorescein; 538 nm/580 nm. For simplicity and flexibility, the MPA-Candida assay was engineered as a two-tube system, run simultaneously under the same experimental conditions.

Tableau 4. Description du test MPA-Candida et pan Fungal. FAM: 6-carboxy-fluoresceine; 465 nm/510 nm; HEX: Hexachloro-fluoresceine; 538 nm/580 nm. Pour simplicité et flexibilité, le test MPA-Candida a été conçu comme un système à deux tubes, exécuté en parallèle sous les mêmes conditions expérimentales.

cellular proteins were removed by a salt precipitation step and the DNA was concentrated and desalted by isopropanol precipitation. The DNA was resuspended in 50 µl of DNA Rehydration Solution, a process optimised by incubating at 65 °C for 1 hour.

Cloned plasmid DNA was purified from bacterial cells using a QIAprep Miniprep Kit (Qiagen) according to the manufacturer instructions. Briefly, samples were subjected to alkaline lysis in buffer PB and neutralised. Cleared lysates were applied to QIAprep purification columns under high-salt concentration affinity binding conditions and eluted in 30 µl of elution buffer. In all cases, the concentration of purified DNA was measured using a NanoDrop 1000 spectrophotometer (Thermo Scientific) and stored at 4 °C until use.

**Primer and hydrolysis probe design.** Fungal ribosomal DNA (rDNA) sequences were retrieved from GenBank and the International Society for Human and Animal Mycoses (ISHAM) ITS database and aligned using CLUSTALW2 or CLUSTAL-Omega (EMBL-EBI; https://www.ebi.ac.uk/Tools/msa/clustalo). Sequences were manipulated and analysed using the BioEdit Sequence Alignment Editor Version 7.2.3. Primers and probes were designed within the rDNA region. Primers used in the MPA-Candida assay were the universal forward primer, LR0 and specifically designed reverse primer, GSCand. A universal pan-fungal primer set ITS3 and LR1 was selected to amplify the region containing the pan-fungal probe. The dual-labelled Candida probes were designed to specifically target the D1/D2 of the LSU rDNA region from at least 15 different Candida species.

The pan-fungal probe was designed based on the internal transcribed spacer (ITS) sequences. MPA probes were designed using the nucleic acid folding and hybridisation prediction software UNAFold (http://unafold.rna.albany.edu). All primers and probes were subjected to reverse BLAST in GenBank (http://blast.ncbi.nlm.nih.gov) to test for cross-homology with other microorganisms. Universal bacterial 16S forward primer 516F: 5′-TGCCAGCAGCGCCGTAA-3′ and reverse primer 806R: 5′-GGACTACCAGGGTATCTAAT-3′<sup>42</sup> set was used for positive control in cross-reactivity experiments. MPA-Candida and pan-Fungal reaction sets are shown in Table 4.

**MPA-Candida and pan-fungal real-time qPCR assay.** The amplification assay was carried out in a LightCycler 480 Instrument II Real-time PCR unit (Roche Diagnostics) using a 384-well plate format. Amplification reactions were performed in 20 µl final volume reactions containing 2× LightCycler 480 Probes Master (Roche Diagnostics), 0.6 µM each primer, optimised concentrations of 0.2 µM pan-Candida THO, 0.4 µM C. krusei-specific THO, 0.4 µM C. glabrata-specific THO, 0.4 µM C. auris-specific THO and 0.4 µM internal control THO. Each THO was combined with the corresponding PCO at a ratio of 1:2. As for the pan-Fungal assay, both the pan-fungal and internal control probes were present at a concentration of 0.4 µM. Template DNA included 1 µl of internal control plasmid DNA (10<sup>6</sup> copies) and 1 µl of either cloned (plasmid) or genomic fungal DNA (1 to 10<sup>6</sup> copies/GEs) per reaction. Real-time PCR conditions were as follows: an initial step of 9 min 30 sec at 95 °C, followed by 50 cycles at 95 °C for 20 sec, 62 °C for 30 sec, and 72 °C for 1 min and temperature maintained at 95 °C for 10 sec before melting curve profiling increases from 20 °C to 80 °C. Two detection channels, FAM (465 nm/510 nm) and HEX (533 nm/580 nm) were activated for fluorescence measurements during the read steps at 72 °C for each experiment. The specificity of the pan-fungal probe was evaluated from the amplification curve whereas those of Candida MPA probes were evaluated from their melt curve profiles. The amplification curve threshold cycle (C<sub>T</sub>) of the pan-Fungal reaction was standardised by an automatic threshold setting whereas for MPA-Candida reaction the threshold line was set at 5 in Fit Points analysis method using the LightCycler 480 software version 1.5 (Roche Diagnostics). Both, the MPA and pan-Fungal reactions contain an internal control to ascertain assay functionality. The internal control probe consists of a unique nucleotide sequence cloned into the pCR 2.1-TOPO vector that has no identity to any entry in the non-redundant nucleotide databases at NCBI. To further demonstrate assay specificity, each probe was evaluated for detection of either genomic fungal DNA or plasmid DNA carrying the corresponding target sequence. In order to prepare cloned plasmid DNAs, first-round PCR amplicons of the C. albicans, C. dubliniensis, C. parapsilosis, C. tropicalis, C. glabrata, C. guilliermondii, C. auris and C. krusei were cloned into the pCR 2.1-TOPO vector using the TOPO TA Cloning system (Invitrogen). The resulting plasmid with insert was quantified and sequenced to confirm amplicon identity.

**MPA-Candida melting curve qualitative analysis.** MPA-Candida assay relies on a novel melting curve analysis for multiple targets in one reaction. Dual-channel melting curves were obtained by measuring the fluorescence of the labelled THOs at different temperatures (from 20 to 80 °C). The fluorescence emission data was...
continuously collected at five acquisitions per degree Celsius and analysed by using the Tm Calling algorithm of the LightCycler 480 Software version 1.5 (Roche Diagnostics). Melting curves were displayed as fluorescence against temperature charts and plotted by representing the negative fluorescence derivative melting curve against temperature (Tm = −dF/dT). The point of inflection represents the melting point of the hybrid THO:PCO in the no DNA control reaction. In the presence of the target sequence, the corresponding probe will be hydrolysed during amplification, which will result in the appearance of a reduced peak in the post-amplification melt curve analysis. The no DNA control melt curve was used for comparison.

**Standard curve.** Standard curve functions to assess unknown target copy number were developed using the pan-Fungal qPCR assay. Recombinant plasmid DNAs of C. albicans, C. dubliniensis, C. krusei, C. glabrata, C. auris, C. parapsilosis, C. tropicalis, C. guilliermondii were serially diluted for detection from 10^6 to 10^2 copies per reaction. Regression lines were obtained by plotting the logarithm of the initial plasmid copy number versus the corresponding Ct and used to determine the sensitivity and efficiency of the assay. Amplification efficiency (E) was calculated by E = 10^(1/b)− 1, where b is the slope of the linear regression equation.

**PCR assay reproducibility.** Intra- and inter-assay reproducibility was assessed by two independent experiments of eight Candida species plasmid DNAs. The coefficient of variation (CV) calculated for Ct data was used as an indicator of relative precision and reproducibility. CV was determined by dividing the standard deviation (SD) by the arithmetic mean of the measured values: CV (%) = (SD/mean value) × 100.

**Data Availability** All data generated or analysed during this study are included in this published article (and its Supplementary Information Files). Materials are available from the corresponding author on reasonable request.

**References**

1. Ruhnke, M. & Schwartz, S. Recent developments in the management of invasive fungal infections in patients with oncohematological diseases. *Ther Adv Hematol* 7, 345–359 (2016).
2. Galimberti, R., Torre, A. C., Baztán, M. C. & Rodriguez-Chiappetta, F. Emerging systemic fungal infections. *Clin Dermatol* 30, 633–50 (2012).
3. Brown, G. D. et al. Hidden killers: human fungal infections. *Sci Transl Med* 4, 165rv13 (2012).
4. Enoch, D. A., Yang, H., Aliyu, S. H. & Micallef, C. The changing epidemiology of invasive fungal infections. in *Methods in Molecular Biology* 1508, 17–85 (Humana Press, New York, NY, 2017).
5. Delaloye, J. & Calandra, T. Invasive candidiasis as a cause of sepsis in the critically ill patient. *Virulence* 5, 161–9 (2014).
6. Perlroth, J., Choi, R. & Spellberg, B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. *Med Mycol* 45, 321–346 (2007).
7. Wisplinghoff, H., Seifert, H., Wenzel, R. P. & Edmond, M. B. Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by *Candida* spp. *Clin Microbiol Infect* 12, 170–77 (2006).
8. Calandra, T., Roberts, J. A., Antonelli, M., Bassetti, M. & Vincent, J. L. Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy. *Crit Care* 20, 125 (2016).
9. Pegorie, M., Denning, D. W. & Welfare, W. Estimating the burden of invasive and serious fungal disease in the United Kingdom. *J Infect* 74, 60–71 (2017).
10. Ahmadi, A. et al. Invasive candidiasis in intensive care unit; consensus statement from an Iranian panel of experts, July 2013. *JR Soc Med Open* 5, 1–10 (2014).
11. Pfaffer, M. A. & Castanheira, M. Nosocomial candidiasis: Antifungal stewardship and the importance of rapid diagnosis. *Med Mycol* 54, 1–22 (2016).
12. Cuenca-Estrella, M. Combinations of antifungal agents in therapy- what value are they? *Antimicrob Chemother* 54, 854–69 (2004).
13. Arendrup, M. C. *Candida* and candidaemia. Susceptibility and epidemiology. *Dan Med J* 60, B4698 (2013).
14. Vazquez, J. A., Sobel, J. D. & Fidel, P. L. *Candida glabrata*: Review of epidemiology, pathogenesis, and clinical disease with comparison to *C. albicans*. *Clin Microbiol Rev* 12, 80–96 (1999).
15. Public Health England. Laboratory surveillance of polymicrobial bacteraemia and fungaemia in England, Wales and Northern Ireland: 2017. *Health Protection Report* 12 (2018).
16. Schelz, S. et al. First hospital outbreak of the globally emerging *Candida auris* in a European hospital. *Antimicrob Resist Infect Control* 5, 1–7 (2016).
17. Louise, B. et al. Guidance for the laboratory investigation, management and infection prevention and control for cases of *Candida auris*. *Public Heal Engl* 6 (2017).
18. Satoh, K. *et al.* *Candida auris* sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. *Microbiol Immunol* 53, 41–44 (2009).
19. Public Health England. Laboratory surveillance of candidaemia in England, Wales and Northern Ireland: 2016. *Health Protection Report* 12 (2017).
20. Hammond, S. P. *et al.* Molecular methods to improve diagnosis and identification of mucormycosis. *J Clin Microbiol* 49, 2151–2153 (2011).
21. Fidler, G., Leiter, E., Kocsube, S., Biro, S. & Paholiczek, M. Validation of a simplex PCR assay enabling reliable identification of clinically relevant *Candida* species. *BMC Infect Dis* 18, 393 (2018).
22. Ostrosky-Zeichner, L. Invasive mycoses: Diagnostic challenges. *Am J Med* 125, 14–24 (2012).
23. Badiee, P. & Hashemizadeh, Z. Opportunistic invasive fungal infections: Diagnosis & clinical management. *Indian J Med Res* 139, 195–204 (2014).
24. Fu, G., Miles, A. & Alphley, L. Multiplex detection and SNP genotyping in a single fluorescence channel. *PLoS One* 7 (2012).
25. Halliday, C. L., Kidd, S. E., Sorrell, T. C. & Chen, S. C. A. Molecular diagnostic methods for invasive fungal disease: The horizon draws nearer? *Pathology* 47, 257–69 (2015).
26. Schoch, C. L. *et al.* Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for fungi. *Proc Natl Acad Sci USA* 109, 6241–6 (2012).
27. Irinyi, L., Lackner, M., de Hoog, G. S. & Meyer, W. DNA barcoding of fungal causing infections in humans and animals. *Fungal Biol* 120, 125–36 (2016).
28. Page, B. T. & Kurtzman, C. P. Rapid identification of *Candida* species and other clinically important yeast species by flow cytometry. *J Clin Microbiol* 43, 4507–4514 (2005).
29. Makene, V. A. Identification of non- *albicans* *Candida* yeasts associated with vulvovaginal candidiasis in tanzania using a combination of multiplex PCR and DNA sequence divergence of the 26S LSU rDNA. *S Afr J Biol Sci* 2, 124–131 (2014).
30. Pérez-Torrado, R. & Querol, A. Opportunistic strains of Saccharomyces cerevisiae: A potential risk sold in food products. Front Microbiol 6, 1–5 (2016).
31. Daniel, H. M. & Meyer, W. Evaluation of ribosomal RNA and actin gene sequences for the identification of ascomycetous yeasts. Int J Food Microbiol 86, 61–78 (2003).
32. Enache-Angoulvant, A. & Hennequin, C. Invasive saccharomyces infection: A comprehensive review. Clin Infect Dis 41, 1559–1568 (2005).
33. Miceli, M. H., Díaz, J. A. & Lee, S. A. Emerging opportunistic yeast infections. Lancet Infect Dis 11, 142–151 (2011).
34. Iriyú, L. et al. International Society of Human and Animal Mycology (ISHAM)-ITS reference DNA barcoding database - The quality controlled standard tool for routine identification of human and animal pathogenic fungi. Med Mycol 53, 313–337 (2015).
35. Kurtzman, C. P. & Robnett, C. J. Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5′ end of the large-subunit (26S) ribosomal DNA gene. J Clin Microbiol 35, 1216–23 (1997).
36. Ferrer, C. et al. Detection and identification of fungal pathogens by PCR and by ITS2 and 5.8S ribosomal DNA typing in ocular infections. J Clin Microbiol 39, 2873–2879 (2001).
37. Chen, Y. C. et al. Identification of medically important yeasts using PCR-based detection of DNA sequence polymorphisms in the internal transcribed spacer 2 region of the rRNA genes. J Clin Microbiol 38, 2302–10 (2000).
38. Loeffler, J. et al. Quantification of fungal DNA by using fluorescence resonance energy transfer and the light cycler system. J Clin Microbiol 38, 586–590 (2000).
39. Chang, S. S. et al. Multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis - a systemic review and meta-analysis. PLoS One 8 (2013).
40. Schabereiter-Gurtner, C., Selitsch, B., Rotter, M. L., Hirschl, A. M. & Willinger, B. Development of novel real-time PCR assays for detection and differentiation of eleven medically important Aspergillus and Candida species in clinical specimens. J Clin Microbiol 45, 906–914 (2007).
41. Centers for Disease Control and Prevention. Recommendations for identification of Candida auris. (2018). Available at, https://www.cdc.gov/fungal/candida-auris/recommendations.html. (Accessed: 30th October 2018).
42. Fredricks, D. N. & Relman, D. A. Improved amplification of microbial DNA from blood cultures by removal of the PCR inhibitor sodium polyanetholesulfonate. J Clin Microbiol 36, 2810–6 (1998).
43. Cubeta, M. A. Characterization of anastomosis groups of binucleate Rhizoctonia species using restriction analysis of an amplified ribosomal DNA gene. Mol Plant Pathol 81, 1395–1400 (1991).
44. White, T. J., Bruns, T., Lee, S. & Taylor, J. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In PCR Protocols: A Guide to Methods and Applications 606–611, https://doi.org/10.3181/00379727-150-39089 (1990).
45. Vilgalys, R. & Hester, M. Rapid genetic identification and mapping of enzymatically amplified ribosomal DNA from several Cryptococcus species. J Bacteriol 172, 4238–46 (1990).

Acknowledgements
This work was supported by an Institutional Links Grant (IL4275673005) from the Newton Fund to J.T.T. and F.H.H. The authors would like to thank Professor Julian Naglik (King’s College London) for Candida strains and Professor Neil Gow, (University of Aberdeen) for access to unpublished C. auris whole genome sequencing data. M.H.J. also thanks the Ministry of Education Malaysia for a PhD scholarship.

Author Contributions
J.T.T., F.H.H. and G.F. conceived the study; M.H.J. conducted the experiments; J.T.T., F.H.H. and E.S.P. supervised the study M.H.J., A.B. and J.T.T. analysed the data; M.H.J. and J.T.T. wrote the manuscript. All authors reviewed and agreed the contents of the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-51198-6.

Competing Interests: G.F. is an employee of Genefirst Ltd. and has shares in the company; Genefirst Ltd. has patents or patent applications related to the subject of this paper. All other authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019